Advertisement

Topics

STAT Plus: With its silence on key questions, Omeros raises doubts about its rare disease drug

04:30 EDT 22 Aug 2017 | STAT

The Seattle biotech Omeros has long told investors it has a potential blockbuster for rare diseases, but it won't answer key questions about clinical data.

Original Article: STAT Plus: With its silence on key questions, Omeros raises doubts about its rare disease drug

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: With its silence on key questions, Omeros raises doubts about its rare disease drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...